Hyperlipidemia NCEP guidelines for adjuvant therapies in children and adolescents

	Lipoprotein Disorders Microchapters
Patient Information
Overview
Causes
Classification Hyperlipoproteinemia Hypolipoproteinemia
Treatment

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Children and adolescents with high-risk hyperlipidemia require lipid-lowering drug therapy, particularly those with familial hypercholesterolemia, despite compliance with lifestyle recommendations.

Adjuvant Therapies in Children and Adolescents

Hyperlipidemia NCEP Recommendations for Adjuvant Therapies in Children and Adolescents^[1] (DO NOT EDIT)

“

The Role of Physical Activity in Management

1) From current pediatric data, it would appear that an exercise program should be included as part of a comprehensive risk factor modification program for the prevention of cardiovascular disease in children and adolescents.

2) Emphasis on regular physical activity rather than improvement in aerobic capacity appears to be the best approach for structuring such a program.

3) More long-term data are needed to completely assess the role of physical activity in risk factor modification for the pediatric population.

Nonpharmacological Therapies

1) In general, dietary recommendations should be consistent with good nutrition, aimed at a proper caloric balance to ensure optimal growth and development while preventing obesity.

”

References

↑ McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP; et al. (2007). "Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing". Circulation. 115 (14): 1948–67. doi:10.1161/CIRCULATIONAHA.107.181946. PMID 17377073.

de:Hyperlipoproteinämie he:היפרליפידמיה sv:Hyperlipidemi

Template:WikiDoc Sources

[pmid17377073-1] McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP; et al. (2007). "Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing". Circulation. 115 (14): 1948–67. doi:10.1161/CIRCULATIONAHA.107.181946. PMID 17377073.

[1]